Inventor · disambiguated record
Samuel Kintz
Also filed as: KINTZ SAMUEL · KINTZ SAMUEL S
10 granted patents·9 pending applications·29 citations·filing 2009–2025
85Inventor score
Top patents by PatentIndex Score
19 records- 0195US9440976B21,7-diazacarbazoles and methods of useGENENTECH INC·Filed 2015·Granted Sep 13, 2016·10 cites·5 claims
- 0290US11807638B25- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinasesENLIVEN INC·Filed 2022·Granted Nov 7, 2023·1 cites·44 claims
- 0385US11767321B25- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinasesENLIVEN INC·Filed 2021·Granted Sep 26, 2023·1 cites·31 claims
- 0482US8623889B2Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereofLYSSIKATOS JOSEPH P·Filed 2011·Granted Jan 7, 2014·7 cites·24 claims
- 0581US12240846B25- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinasesENLIVEN INC·Filed 2023·Granted Mar 4, 2025·0 cites·14 claims
- 0680US9187462B2Substituted quinazolines as serine/threonine kinase inhibitorsBLAKE JAMES F·Filed 2012·Granted Nov 17, 2015·6 cites·21 claims
- 0780US8501765B2Diazacarbazoles and methods of useCHEN HUIFEN·Filed 2009·Granted Aug 6, 2013·4 cites·37 claims
- 0873US2025236621A15- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinasesENLIVEN INC·Filed 2025·Application pending·0 cites
- 0966US11807649B2Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2ENLIVEN THERAPEUTICS INC·Filed 2022·Granted Nov 7, 2023·0 cites·44 claims
- 1066US2014171407A11,7-diazacarbazoles and methods of useGENENTECH INC·Filed 2014·Application pending·0 cites
- 1165US2023382923A1Fused tetracyclic quinazoline derivatives as inhibitors of erbb2ENLIVEN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1259US2024287062A1Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinasesENLIVEN INC·Filed 2022·Application pending·0 cites
- 1358US9216980B2Methods of use of diazacarbazoles for treating cancerGENENTECH INC·Filed 2014·Granted Dec 22, 2015·0 cites·37 claims
- 1457US2025136595A1Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2ENLIVEN INC·Filed 2022·Application pending·0 cites
- 1556US9206175B2Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereofGENENTECH INC·Filed 2013·Granted Dec 8, 2015·0 cites·22 claims
- 1655US2013261104A1Methods of use of diazacarbazoles for treating cancerGENENTECH INC·Filed 2013·Application pending·0 cites
- 1751US2024116921A1Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2ENLIVEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1850US2024043420A17-azaindole compounds for inhibition of bcr-abl tyrosine kinasesENLIVEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1948US2016060262A1Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses ThereofGENENTECH INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Samuel Kintz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →